Skip to content

TRINITY BIOTECH PLC

TRIB

CIK 0000888721 · In Vitro & In Vivo Diagnostic Substances · Nasdaq

← back to feed
Revenue (TTM)
$61.56M
+8.3% YoY FY Dec 2025
Net Income (TTM)
−$31.22M
+15.3% YoY FY Dec 2025
EPS Diluted (TTM)
—
FY Dec 2025
Gross Margin
34.8%
FY Dec 2025
Operating Margin
-34.4%
FY Dec 2025
Net Margin
-50.7%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
$5.17M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
374.21M sh
FY Dec 2025

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings